Neurocrine Bioscienc
(NBIX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2014 | 03-2014 | 12-2013 | 09-2013 | 06-2013 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -25,223 | -11,842 | -46,090 | -35,448 | -24,317 |
| Depreciation Amortization | 1,980 | 795 | 3,514 | 2,623 | 1,705 |
| Accounts receivable | N/A | 850 | 13,528 | 13,944 | 14,094 |
| Other Working Capital | -171 | -379 | 12,097 | 13,430 | 14,231 |
| Other Operating Activity | 3,682 | 809 | -12,656 | -13,277 | -13,661 |
| Operating Cash Flow | $-19,732 | $-9,767 | $-29,607 | $-18,728 | $-7,948 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -123,268 | -65,516 | 5,953 | -15,073 | -13,793 |
| PPE Investments | -859 | -215 | -505 | -316 | -323 |
| Other Investing Activity | 0 | 0 | -108 | 0 | 32 |
| Investing Cash Flow | $-124,127 | $-65,731 | $5,340 | $-15,389 | $-14,084 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 136,515 | 136,241 | 5,302 | 5,252 | 2,591 |
| Financing Cash Flow | $136,515 | $136,241 | $5,302 | $5,252 | $2,591 |
| Beginning Cash Position | 44,789 | 44,789 | 63,754 | 63,754 | 63,754 |
| End Cash Position | 37,445 | 105,532 | 44,789 | 34,889 | 44,313 |
| Net Cash Flow | $-7,344 | $60,743 | $-18,965 | $-28,865 | $-19,441 |
| Free Cash Flow | |||||
| Operating Cash Flow | -19,732 | -9,767 | -29,607 | -18,728 | -7,948 |
| Capital Expenditure | -904 | -255 | -545 | -354 | -323 |
| Free Cash Flow | -20,636 | -10,022 | -30,152 | -19,082 | -8,271 |